Johnson & Johnson
Johnson & Johnson (JNJ) will report its third-quarter results before the market opens on October 17. The stock is currently trading just shy of its record-high and investors remain very upbeat on the company. Improvements in the overall economy have helped the company’s consumer goods segments, and its drug and medical devices segments have been strong as well. The company has a solid earnings track record, posting better than expected profits for 20 straight quarters, but sales have been weaker than expected the last three quarters. Wall Street has opted to focus on the company’s bottom line, and that should be the case again this quarter. The consensus calls for earnings of $1.80 per share, but the street expects another earnings beat, with a whisper of $1.81 for the quarter. During the same period last year the company earned $1.68. InvestorsObserverJNJ gives the stock an overall score of 62.